Giotrif
(Afatinib)
(40 mg)
(28)
(Таб)
Giortif (afatinib) 40 мг 28 бат. Natco, Іndia
In Stock
Indications
Giotrif is indicated as monotherapy for the treatment of:
locally advanced or metastatic NSCLC with mutation(s) of the epidermal growth factor receptor (EGFR) in patients who have not previously received EGFR tyrosine kinase inhibitors;
locally advanced or metastatic squamous cell NSCLC in individuals with disease progression during or after platinum-based chemotherapy
-
Commercial name:Giotrif
-
Сhemical name:Afatinib
-
Dosage:40 mg
-
Quantity:28
-
Release form:Таб
-
Производитель:Natco, Индия
No reviews yet